{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:13:26Z","timestamp":1789017206055,"version":"build-2803163510"},"reference-count":15,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2023,12,3]],"date-time":"2023-12-03T00:00:00Z","timestamp":1701561600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>While chimeric antigen receptor (CAR) T\u2010cell therapy has revolutionized the treatment outcomes of relapsed\/refractory hematological malignancies, this therapy is associated with post\u2010treatment cytopenias, which can pose a challenge to its safe administration. This study describes the management of post\u2010CAR T cytopenias using the thrombopoietin mimetic eltrombopag.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective analysis included adult patients with lymphoma or myeloma who received CAR T\u2010cell therapy at two academic medical centers. Eltrombopag was initiated for patients who had persistent high\u2010grade leukopenia and\/or thrombocytopenia beyond 21\u2009days post\u2010CAR T infusion. Risk factors and outcomes were assessed and compared for patients who did or did not receive eltrombopag.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among the 185 patients analyzed, a majority (88%) experienced thrombocytopenia or leukopenia at day +30 post\u2010CAR T infusion. A total of 42 patients met the criteria for eltrombopag treatment and initiated therapy. Patients who received eltrombopag were more likely to have pre\u2010existing cytopenias at lymphodepletion, receive bridging therapy, experience an infection, or require intensive care. Recovery from cytopenias occurred within 180\u2009days for a majority (94%) of patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The use of eltrombopag for post\u2010CAR T leukopenia and thrombocytopenia was considered safe without any significant toxicities. The use of eltrombopag for post\u2010CAR T cytopenias might be effective in a high\u2010risk patient population but requires further study.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ejh.14141","type":"journal-article","created":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T06:14:37Z","timestamp":1701670477000},"page":"538-546","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Safety and efficacy of eltrombopag in patients with post\u2010<scp>CAR T<\/scp> cytopenias"],"prefix":"10.1111","volume":"112","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9534-0512","authenticated-orcid":false,"given":"William","family":"Wesson","sequence":"first","affiliation":[{"name":"Division of Hematologic Malignancies &amp; Cellular Therapeutics University of Kansas Medical Center  Westwood Kansas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nausheen","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies &amp; Cellular Therapeutics University of Kansas Medical Center  Westwood Kansas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliya","family":"Rashid","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies &amp; Cellular Therapeutics University of Kansas Medical Center  Westwood Kansas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carine","family":"Tabak","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies &amp; Cellular Therapeutics University of Kansas Medical Center  Westwood Kansas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emerson","family":"Logan","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies &amp; Cellular Therapeutics University of Kansas Medical Center  Westwood Kansas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Marchena\u2010Burgos","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies &amp; Cellular Therapeutics University of Kansas Medical Center  Westwood Kansas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maggie","family":"Nelson","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies &amp; Cellular Therapeutics University of Kansas Medical Center  Westwood Kansas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Davis","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology Medical University of South Carolina  Charleston South Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"McGann","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology Medical University of South Carolina  Charleston South Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyla","family":"Shune","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies &amp; Cellular Therapeutics University of Kansas Medical Center  Westwood Kansas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Hoffmann","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies &amp; Cellular Therapeutics University of Kansas Medical Center  Westwood Kansas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Al\u2010Ola","family":"Abdallah","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies &amp; Cellular Therapeutics University of Kansas Medical Center  Westwood Kansas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamza","family":"Hashmi","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology Medical University of South Carolina  Charleston South Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,12,3]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817226"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-703751"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.148"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.7554"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14061501"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-019-0487-3"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30864-7"},{"key":"e_1_2_11_11_1","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE).Version 5.0 Published: November 27 2017. Last accessed March 9 2022 athttps:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_8.5x11.pdf"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008066"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277\u2010022\u201004889\u20106"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002509"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.212845"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.14141","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T05:13:22Z","timestamp":1714626802000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.14141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,3]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10.1111\/ejh.14141"],"URL":"https:\/\/doi.org\/10.1111\/ejh.14141","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,3]]},"assertion":[{"value":"2023-08-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}